Original article: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
(8 August, 2011)
Free
J P Clancy, Steven M Rowe, Frank J Accurso, Moira L Aitken, Raouf S Amin, Melissa A Ashlock, Manfred Ballmann, Michael P Boyle, Inez Bronsveld, Preston W Campbell, Kris De Boeck, Scott H Donaldson, Henry L Dorkin, Jordan M Dunitz, Peter R Durie, Manu Jain, Anissa Leonard, Karen S McCoy, Richard B Moss, Joseph M Pilewski, Daniel B Rosenbluth, Ronald C Rubenstein, Michael S Schechter, Martyn Botfield, Claudia L Ordoñez, George T Spencer-Green, Laurent Vernillet, Steve Wisseh, Karl Yen, Michael W Konstan
